$25 Million Verdict Against American Biltrite for Asbestos Floor Tiles That Caused Mesothelioma
Won by Weitz & Luxenberg.
A New York jury awarded $25 million, including $5 million in punitive damages, to a retired flooring installer who developed mesothelioma after decades of cutting and removing American Biltrite Amtico asbestos floor tiles.
What happened
For years, the plaintiff worked as a flooring installer, regularly cutting, fitting, and removing American Biltrite's Amtico-brand floor tiles. The tiles contained asbestos, and the work generated fine dust that he breathed in day after day. He later developed mesothelioma, a cancer of the lining of the lungs caused by asbestos exposure.
Weitz and Luxenberg attorneys Brittany Russell and Pierre Ratzki tried the case before Justice Judy J. Kim in New York County Supreme Court, part of the New York City Asbestos Litigation (NYCAL) docket. The central question at trial was not only whether the tiles caused the illness, but whether American Biltrite had any legitimate reason to keep selling asbestos tiles in the first place.
The plaintiff's team introduced a 1981 patent showing that American Biltrite had already developed the ability to manufacture a non-asbestos floor tile using the same equipment and production process it used for its asbestos version. The company had a workable path to a safer product and chose not to take it. That evidence drove the punitive damages claim.
On April 29, 2026, the jury returned a verdict of $25 million. The compensatory portion totaled $20 million: $10 million for past pain and suffering and $10 million for future pain and suffering. The jury added $5 million in punitive damages against American Biltrite. Following the verdict, American Biltrite asked the court to stay entry of judgment pending resolution of post-trial motions. As of the time of publication, no reduction or appeal ruling had been reported.
Sources
This account is drawn from contemporaneous public reporting and the court record.
- 1.New York Law Journal: Weitz & Luxenberg Wins $25M Verdict in Asbestos Tile Suit (April 2026)
- 2.MesoWatch: New York Jury Awards $25M in American Biltrite Asbestos Tile Case (May 2026)·Archived copy
- 3.Mealey's Litigation Reports: New York Jury Awards $25 Million In Asbestos Tile Case (2026)·Archived copy
More proven verdicts from Weitz & Luxenberg
All Weitz & Luxenberg proven verdicts →As co-lead counsel in the federal Roundup multidistrict litigation and the first firm to sue Monsanto in 2015, Weitz and Luxenberg helped negotiate a $10.9 billion settlement resolving approximately 125,000 non-Hodgkin lymphoma claims against Bayer-owned Monsanto.
As chair of the plaintiffs' negotiating committee and Liaison Counsel in the Vioxx multidistrict litigation, Russ Herman directed the negotiations that produced a $4.85 billion settlement with Merck resolving approximately 45,000 to 50,000 personal-injury claims.
Ellen Relkin served as court-appointed co-lead plaintiffs counsel in the DePuy ASR hip implant MDL, helping negotiate a $2.5 billion settlement for roughly 8,000 patients who required revision surgery after the metal-on-metal device failed.
Hours before opening arguments in the first federal opioid bellwether trial, Cuyahoga and Summit counties in Ohio secured a $260 million settlement from distributors AmerisourceBergen, Cardinal Health, and McKesson, plus manufacturer Teva.
Related product liability verdicts
Sullivan Papain was among the firms representing New York State against Philip Morris, R.J. Reynolds, Brown & Williamson, and Lorillard, securing a $25 billion recovery through the 1998 Master Settlement Agreement.
C. Steven Yerrid, the youngest of Florida's 11-lawyer 'Dream Team,' added racketeering and conspiracy charges that tripled the damages ceiling, helping the state secure what was then the largest civil settlement in American history against the tobacco industry.
After fifteen years of litigation and three failed bankruptcy maneuvers by Johnson and Johnson subsidiaries, Ashcraft and Gerel attorneys R. Bryant McCulley and Michelle Parfitt helped negotiate a global, uncapped settlement of at least $5.5 billion covering approximately 76,000 ovarian-cancer claims.
As chair of the plaintiffs' negotiating committee and Liaison Counsel in the Vioxx multidistrict litigation, Russ Herman directed the negotiations that produced a $4.85 billion settlement with Merck resolving approximately 45,000 to 50,000 personal-injury claims.